Walleye Capital
KLRS

Walleye Capital’s Kalaris Therapeutics KLRS Stock Holding History

Walleye Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,225
Closed -$94.7K – 5118
2025
Q4 		$94.7K Buy
+11,225
New +$71.8K ﹤0.01% 3895
2021
Q2 		– Sell
-1,385
Closed -$745 – 1543
2021
Q1 		$745 Buy
+1,385
New +$1.16M 0.04% 403

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Walleye Capital's KLRS Position: Q1 2026 in Review

Walleye Capital sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 11,225 shares — an estimated $94.7K sold.

Walleye Capital first reported a position in KLRS in Q1 2021 and held it in 2 quarters. The position peaked at $94.7K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Walleye Capital reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 11,225 Kalaris Therapeutics shares in Q1 2026, an estimated $94.7K.
  • Walleye Capital first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 2 quarters.
  • Walleye Capital's Kalaris Therapeutics position peaked at $94.7K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.